≡ Risteys
R8

Documentation Changelog GitHub Contact & Feedback

Glucagon-like peptide-1 (GLP-1) analogues

PheWeb

GLP1ANA

No definition available.

Endpoint definition

↥
FinnGen phenotype data

356077 individuals

diagram downward connector

Apply sex-specific rule None

356077

diagram downward connector

Check conditions None

356077

diagram downward connector
diagram bullet

Filter registries

Medicine purchases: ATC A10BH

18196

diagram downward connector

Check pre-conditions, main-only, mode, ICD version None

15725

diagram downward connector
diagram bullet

Check minimum number of events

Min. number of events 3

15725

diagram downward connector

Include endpoints None

15725

diagram downward connector
GLP1ANA

Extra metadata

First used in FinnGen datafreeze DF2

Summary Statistics

↥

Key figures

All Female Male
Number of individuals 15725 6779 8946
Unadjusted prevalence (%) 4.42 3.42 5.68
Mean age at first event (years) 65.31 64.67 65.79

Mortality

Follow-up Absolute risk HR [95% CI] p N
1998–2019 0.07 4.18 [3.55, 4.91] 2.1e-66 1958
15 years 0.01 1.59 [1.34, 1.90] 1.2e-7 727
5 years 0.01 4.79 [4.16, 5.51] <1e-100 1045
1 year 0.00 4.43 [3.66, 5.36] 1.0e-52 188

Age distribution of first events

Year distribution of first events

Cumulative Incidence

Correlations

↥

Index endpoint: GLP1ANA – Glucagon-like peptide-1 (GLP-1) analogues
GWS hits:

Survival analyses between endpoints

↥

Plot

before Glucagon-like peptide-1 (GLP-1) analogues
after Glucagon-like peptide-1 (GLP-1) analogues

loading spinner Loading survival analyses plot

Drugs most likely to be purchased after Glucagon-like peptide-1 (GLP-1) analogues

↥